
Spectrum Pharmaceuticals Revenue | SPPI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.1 M | - | - | - | 109 M | 128 M | 146 M | 137 M | 187 M | 143 M | 255 M | 181 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 255 M | 10.1 M | 144 M |
Quarterly Revenue Spectrum Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.4 M | 25.3 M | 24.2 M | 30.5 M | 28.6 M | 36.4 M | 34.3 M | 29.1 M | 50 M | 30.3 M | 30.9 M | 35.2 M | 34.8 M | 28.5 M | 35.1 M | 38.4 M | 51.7 M | 47.9 M | 46.9 M | 40.1 M | 40.5 M | 41.4 M | 32.2 M | 29.3 M | 70.1 M | 69 M | 68.7 M | 59.9 M | 53 M | 51 M | 45.4 M | 43.6 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70.1 M | 15.6 M | 40.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Syndax Pharmaceuticals
SNDX
|
172 M | $ 8.71 | -4.16 % | $ 755 M | ||
|
Aquestive Therapeutics
AQST
|
44.5 M | $ 3.47 | -6.48 % | $ 371 M | ||
|
Pliant Therapeutics
PLRX
|
1.58 M | $ 0.59 | -4.42 % | $ 36.2 M | ||
|
Jaguar Health
JAGX
|
11.5 M | $ 0.24 | -27.06 % | $ 560 K | ||
|
Arvinas
ARVN
|
263 M | $ 6.41 | -4.9 % | $ 454 M | ||
|
Cerus Corporation
CERS
|
234 M | $ 1.86 | -2.37 % | $ 355 M | ||
|
Beam Therapeutics
BEAM
|
140 M | $ 20.87 | -0.36 % | $ 2.06 B | ||
|
Inhibrx
INBX
|
1.8 M | $ 68.81 | -7.43 % | $ 3.24 B | ||
|
Scholar Rock Holding Corporation
SRRK
|
33.2 M | $ 48.09 | -4.54 % | $ 5.52 B | ||
|
Revolution Medicines
RVMD
|
11.6 M | $ 161.01 | 0.99 % | $ 30.6 B | ||
|
Entera Bio Ltd.
ENTX
|
42 K | $ 3.29 | 0.15 % | $ 152 M | ||
|
Flexion Therapeutics, Inc.
FLXN
|
85.6 M | - | - | $ 459 M | ||
|
Legend Biotech Corporation
LEGN
|
627 M | $ 15.21 | -5.53 % | $ 5.61 B | ||
|
CytomX Therapeutics
CTMX
|
76.2 M | $ 2.04 | -0.73 % | $ 281 M | ||
|
China SXT Pharmaceuticals
SXTC
|
1.14 M | $ 2.67 | 2.9 % | $ 1.81 M | ||
|
Krystal Biotech
KRYS
|
389 M | $ 308.83 | -2.21 % | $ 8.94 B | ||
|
Kura Oncology
KURA
|
67.5 M | $ 6.91 | -6.05 % | $ 606 M | ||
|
Inhibikase Therapeutics
IKT
|
261 K | $ 1.31 | 0.38 % | $ 129 M | ||
|
Protara Therapeutics
TARA
|
2.95 M | $ 2.28 | -5.21 % | $ 97.7 M | ||
|
Heron Therapeutics
HRTX
|
155 M | $ 0.25 | -5.3 % | $ 41.7 M | ||
|
Inovio Pharmaceuticals
INO
|
65.3 K | $ 1.76 | 2.63 % | $ 82.5 M | ||
|
Aytu BioScience
AYTU
|
57.6 M | $ 2.66 | -0.37 % | $ 32.8 M | ||
|
Heat Biologics, Inc.
HTBX
|
2.95 M | - | -5.76 % | $ 99.8 M | ||
|
Innoviva
INVA
|
411 M | $ 18.42 | 0.03 % | $ 1.24 B | ||
|
BioCardia
BCDA
|
58 K | $ 0.77 | -0.08 % | $ 5.13 M | ||
|
Bio-Techne Corporation
TECH
|
1.22 B | $ 72.69 | -0.01 % | $ 11.3 B | ||
|
Kindred Biosciences, Inc.
KIN
|
42.2 M | - | 0.11 % | $ 419 M | ||
|
Alterity Therapeutics Limited
ATHE
|
109 K | $ 1.52 | -8.16 % | $ 9.72 B | ||
|
Shineco, Inc.
TYHT
|
23.7 M | - | -3.90 % | $ 97.2 M | ||
|
Certara
CERT
|
419 M | $ 10.56 | -1.12 % | $ 1.69 B | ||
|
Anika Therapeutics
ANIK
|
113 M | $ 13.26 | -0.15 % | $ 190 M | ||
|
Processa Pharmaceuticals
PCSA
|
5 K | $ 1.59 | -5.92 % | $ 2.08 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
761 M | $ 63.61 | -2.11 % | $ 6.61 B | ||
|
Progenity, Inc.
PROG
|
74.3 M | - | -3.47 % | $ 164 M | ||
|
Strongbridge Biopharma plc
SBBP
|
30.7 M | - | 1.52 % | $ 136 M | ||
|
Nektar Therapeutics
NKTR
|
55.2 M | $ 30.23 | -7.1 % | $ 510 M | ||
|
Innate Pharma S.A.
IPHA
|
9 M | $ 0.87 | -7.57 % | $ 77.9 M | ||
|
Seneca Biopharma, Inc.
SNCA
|
13.5 K | - | -1.19 % | $ 28.7 M | ||
|
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 60.42 | -1.64 % | $ 11.6 B | ||
|
Matinas BioPharma Holdings
MTNB
|
1.1 M | $ 0.75 | -9.23 % | $ 4.11 M | ||
|
Enanta Pharmaceuticals
ENTA
|
63 M | $ 7.6 | -4.82 % | $ 220 M | ||
|
Lipocine
LPCN
|
1.98 M | $ 1.47 | -2.33 % | $ 8.01 M |